TABLE 1.

Summary of current randomized, placebo-controlled clinical trials of IL-6 inhibitors for COVID-19.

Drugs	Indication	Interventions	Multicenter	No. of cases	Phase of trail	Country	Registered no
Clazakizumab	Life-threatening COVID-19 infection	Clazakizumab vs. placebo	No	30	II	United States	NCT04381052
Clazakizumab	Life-threatening COVID-19 infection	Clazakizumab 25 vs. 12.5 mg vs. placebo	No	90	II	United States	NCT04343989
Clazakizumab	Life-threatening COVID-19 infection	Clazakizumab vs. placebo	No	30	II	United States	NCT04363502
Tocilizumab	COVID-19 pneumonia	Tocilizumab vs. placebo	Yes	379	III	United States	NCT04372186
Tocilizumab	Moderate to severe COVID-19 pneumonia	Tocilizumab vs. placebo	Yes	450	III	United States	NCT04320615
Tocilizumab	Severe COVID-19 pneumonia	Remdesivir + tocilizumab vs. Remdesivir + placebo	Yes	450	III	United States	NCT04409262
Tocilizumab	COVID-19 disease	Tocilizumab vs. placebo	Yes	100	II	Switzerland	NCT04335071
Tocilizumab	SARS-CoV-2 infection and evidence of systemic inflammation	Tocilizumab vs. placebo	Yes	243	III	United States	NCT04356937
Sarilumab	Hospitalized COVID-19 patients	Sarilumab vs. placebo	Yes	1912	II//III	United States	NCT04315298
Sarilumab	Severe or critical COVID-19	Sarilumab dose 1 and dose 2 vs. placebo	Yes	409	III	Argentina	NCT04327388
Olokizumab	Severe COVID-19	RPH-104 a vs. Olokizumab vs. placebo	Yes	372	III	Russia	NCT04380519

Data resource: ClinicalTials.gov, accessed on 9 September 2020.

^aRPH-104, a novel heterodimeric fusion protein, capable of inhibition of human IL-1 beta/IL-1F2 signaling pathway.